Clinical Trial: Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07619937) titled 'Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma' on May 27.

Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and regorafenib as first-line therapy in patients with locally advanced or metastatic cholangiocarcinoma.

The main questions it aims to answer are:

1. What is the objective response rate (ORR) of this combination regimen according to RECIST 1.1 criteria

2. What are the disease control rate (DCR), progres...